CDER’s the latest proposal to withdraw the accelerated approval of Makena (HPC) was dependent on a significant randomized trial that failed to confirm the advantage of this drug to newborns or lessen the potential risk of PTB. In earning the decision to suggest Makena’s withdrawal, CDER also reviewed success from prior experiments of progesti